
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC is strategically positioned for growth through its innovative ImmTAX platform, with multiple therapeutic programs in oncology, infectious disease, and autoimmune conditions, supporting a robust pipeline that enhances its long-term revenue potential. The company's flagship product, KIMMTRAK, has consistently surpassed quarterly sales consensus in the majority of its launch period, demonstrating strong market demand and performance, particularly in the treatment of unresectable or metastatic uveal melanoma. Furthermore, while U.S. market penetration appears to be stabilizing, future revenue growth is anticipated from expanded international launches and improved treatment duration, indicating a solid foundation for sustained commercial expansion.
Bears say
Immunocore Holdings faces significant financial risks due to underwhelming clinical data from key melanoma trials, with reported overall response rates of only 11% and 6% for monotherapy treatments, which fell short of market expectations. Additionally, emerging competition from IDYA’s darovasertib poses a threat to KIMMTRAK's market potential in the HLA-A2+ mUM segment, with expected updates that could negatively impact the company's market share. Coupled with potential research and development setbacks, regulatory challenges, and the risk of dilutive financing, these factors contribute to a negative outlook for Immunocore Holdings's stock.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares